amsb2xfr

Property	Value
?:abstract	A safe and effective vaccine against COVID-19 is urgently needed in quantities sufficient to immunise large populations. We report the preclinical development of two BNT162b vaccine candidates, which contain lipid-nanoparticle (LNP) formulated nucleoside-modified mRNA encoding SARS-CoV-2 spike glycoprotein-derived immunogens. BNT162b1 encodes a soluble, secreted, trimerised receptor-binding domain (RBD-foldon). BNT162b2 encodes the full-length transmembrane spike glycoprotein, locked in its prefusion conformation (P2 S). The flexibly tethered RBDs of the RBD-foldon bind ACE2 with high avidity. Approximately 20% of the P 2S trimers are in the two-RBD ‘down,’ one-RBD ‘up’ state. In mice, one intramuscular dose of either candidate elicits a dose-dependent antibody response with high virus-entry inhibition titres and strong TH1 CD4+ and IFNγ+ CD8+ T-cell responses. Prime/boost vaccination of rhesus macaques with BNT162b candidates elicits SARS-CoV-2 neutralising geometric mean titres 8.2 to 18.2 times that of a SARS-CoV-2 convalescent human serum panel. The vaccine candidates protect macaques from SARS-CoV-2 challenge, with BNT162b2 protecting the lower respiratory tract from the presence of viral RNA and with no evidence of disease enhancement. Both candidates are being evaluated in phase 1 trials in Germany and the United States. BNT162b2 is being evaluated in an ongoing global, pivotal Phase 2/3 trial (NCT04380701, NCT04368728).
is ?:annotates of	<https://research.tib.eu/covid-19/entity/amsb2xfr_hasAnnotation_C0023779> <https://research.tib.eu/covid-19/entity/amsb2xfr_hasAnnotation_C0028621> <https://research.tib.eu/covid-19/entity/amsb2xfr_hasAnnotation_C0035736> <https://research.tib.eu/covid-19/entity/amsb2xfr_hasAnnotation_C1415205> <https://research.tib.eu/covid-19/entity/amsb2xfr_hasAnnotation_C1422064> <https://research.tib.eu/covid-19/entity/amsb2xfr_hasAnnotation_C1423842> <https://research.tib.eu/covid-19/entity/amsb2xfr_hasAnnotation_C1425583> <https://research.tib.eu/covid-19/entity/amsb2xfr_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Vogel%2C_Annette_B.%3B_Kanevsky%2C_Isis%3B_Che%2C_Ye%3B_Swanson%2C_Kena_A.%3B_Muik%2C_Alexander%3B_Vormehr%2C_Mathias%3B_Kranz%2C_Lena_M.%3B_Walzer%2C_Kerstin_C.%3B_Hein%2C_Stephanie%3B_G%C3%BCler%2C_Alptekin%3B_Loschko%2C_Jakob%3B_Maddur%2C_Mohan_S.%3B_Ota-Setlik%2C_Ayuko%3B_Tompkins%2C_Kristin%3B_Cole%2C_Journey%3B_Lui%2C_Bonny_G.%3B_Ziegenhals%2C_Thomas%3B_Plaschke%2C_Arianne%3B_Eisel%2C_David%3B_Dany%2C_Sarah_C.%3B_Fesser%2C_Stephanie%3B_Erbar%2C_Stephanie%3B_Bates%2C_Ferdia%3B_Schneider%2C_Diana%3B_Jesionek%2C_Bernadette%3B_S%C3%A4nger%2C_Bianca%3B_Wallisch%2C_Ann-Kathrin%3B_Feuchter%2C_Yvonne%3B_Junginger%2C_Hanna%3B_Krumm%2C_Stefanie_A.%3B_Heinen%2C_Andr%C3%A9_P.%3B_Adams-Quack%2C_Petra%3B_Schlereth%2C_Julia%3B_Schille%2C_Stefan%3B_Kr%C3%B6ner%2C_Christoph%3B_de_la_Caridad_G%C3%BCimil_Garcia%2C_Ram%C3%B3n%3B_Hiller%2C_Thomas%3B_Fischer%2C_Leyla%3B_Sellers%2C_Rani_S.%3B_Choudhary%2C_Shambhunath%3B_Gonzalez%2C_Olga%3B_Vascotto%2C_Fulvia%3B_Gutman%2C_Matthew_R.%3B_Fontenot%2C_Jane_A.%3B_Hall-Ursone%2C_Shannan%3B_Brasky%2C_Kathleen%3B_Griffor%2C_Matthew_C.%3B_Han%2C_Seungil%3B_Su%2C_Andreas_A.H.%3B_Lees%2C_Joshua_A.%3B_Nedoma%2C_Nicole_L.%3B_Mashalidis%2C_Ellene_H.%3B_Sahasrabudhe%2C_Parag_V.%3B_Tan%2C_Charles_Y.%3B_Pavliakova%2C_Danka%3B_Singh%2C_Guy%3B_Fontes-Garfias%2C_Camila%3B_Pride%2C_Michael%3B_Scully%2C_Ingrid_L.%3B_Ciolino%2C_Tara%3B_Obregon%2C_Jennifer%3B_Gazi%2C_Michal%3B_Carrion%2C_Ricardo%3B_Alfson%2C_Kendra_J.%3B_Kalina%2C_Warren_V.%3B_Kaushal%2C_Deepak%3B_Shi%2C_Pei-Yong%3B_Klamp%2C_Thorsten%3B_Rosenbaum%2C_Corinna%3B_Kuhn%2C_Andreas_N.%3B_T%C3%BCreci%2C_%C3%96zlem%3B_Dormitzer%2C_Philip_R.%3B_Jansen%2C_Kathrin_U.%3B_Sahin%2C_Ugur>
?:doi	<https://research.tib.eu/covid-19/entity/10.1101/2020.12.11.421008>
?:doi	10.1101/2020.12.11.421008
?:externalLink	<https://doi.org/10.1101/2020.12.11.421008>
?:journal	bioRxiv
?:license	biorxiv
?:pdf_json_files	document_parses/pdf_json/3d00ff4c8f676918f1b0375f3f6a35bf0bb7219b.json
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/amsb2xfr_HAS_C0035736_AUGMENTS_C0012634> <https://research.tib.eu/covid-19/entity/amsb2xfr_HAS_C1522002_INTERACTS_WITH_C1422064>
?:sha_id	<https://research.tib.eu/covid-19/entity/3d00ff4c8f676918f1b0375f3f6a35bf0bb7219b>
?:source	BioRxiv; WHO
?:title	BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-12-11

Property

Value

?:abstract

A safe and effective vaccine against COVID-19 is urgently needed in quantities sufficient to immunise large populations. We report the preclinical development of two BNT162b vaccine candidates, which contain lipid-nanoparticle (LNP) formulated nucleoside-modified mRNA encoding SARS-CoV-2 spike glycoprotein-derived immunogens. BNT162b1 encodes a soluble, secreted, trimerised receptor-binding domain (RBD-foldon). BNT162b2 encodes the full-length transmembrane spike glycoprotein, locked in its prefusion conformation (P2 S). The flexibly tethered RBDs of the RBD-foldon bind ACE2 with high avidity. Approximately 20% of the P 2S trimers are in the two-RBD ‘down,’ one-RBD ‘up’ state. In mice, one intramuscular dose of either candidate elicits a dose-dependent antibody response with high virus-entry inhibition titres and strong TH1 CD4+ and IFNγ+ CD8+ T-cell responses. Prime/boost vaccination of rhesus macaques with BNT162b candidates elicits SARS-CoV-2 neutralising geometric mean titres 8.2 to 18.2 times that of a SARS-CoV-2 convalescent human serum panel. The vaccine candidates protect macaques from SARS-CoV-2 challenge, with BNT162b2 protecting the lower respiratory tract from the presence of viral RNA and with no evidence of disease enhancement. Both candidates are being evaluated in phase 1 trials in Germany and the United States. BNT162b2 is being evaluated in an ongoing global, pivotal Phase 2/3 trial (NCT04380701, NCT04368728).

is ?:annotates of